NCT05114746 2026-03-16
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
Clinical Trials
77 trialsNCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT05670106 2026-02-13
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Novartis
Phase 2 Active not recruiting
NCT05160597 2026-02-12
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04777071 2026-01-09
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
Phase 2 Active not recruiting
NCT05562791 2026-01-07
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT07301827 2025-12-24
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Recruiting
NCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT07209878 2025-10-07
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
Phase 2/3 Recruiting
NCT05324332 2025-09-22
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
Peking Union Medical College Hospital
Phase NA Recruiting
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT06200103 2025-09-11
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT07052214 2025-09-10
BiPASS
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT04951817 2025-08-29
68Ga-PSMA PET/CT for Ra223 Assessment
Chang Gung Memorial Hospital
Phase NA Recruiting
NCT04576871 2025-08-28
Re-treatment 225Ac-J591 for mCRPC
Weill Medical College of Cornell University
Phase EARLY_PHASE1 Completed
NCT04147494 2025-08-12
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT07117760 2025-08-12
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Recruiting
NCT05547386 2025-07-18
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 3 Completed
NCT06067269 2025-07-15
HEATWAVE
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT04886986 2025-06-27
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Suspended
NCT03582774 2025-05-13
PSMA SRT
Jonsson Comprehensive Cancer Center
Phase 3 Active not recruiting
NCT03768349 2025-04-06
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT04597411 2025-03-21
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Recruiting
NCT06044857 2025-03-12
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT02920229 2025-01-09
GaPSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase NA Completed
NCT03453528 2025-01-08
BASKET PSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase NA Completed
NCT04716725 2024-10-16
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Active not recruiting
NCT02952469 2024-09-03
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
University of Iowa
Phase EARLY_PHASE1 Completed
NCT05847348 2024-07-03
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT06484361 2024-07-03
PET/MRI to Stage Prostate Cancer Patients
IRCCS San Raffaele
Phase 2 Recruiting
NCT03276572 2024-06-13
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT03762759 2024-05-17
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
Phase 2 Active not recruiting
NCT06355843 2024-04-09
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.
The First Affiliated Hospital of Anhui Medical University
Phase NA Suspended
NCT03822871 2024-03-21
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Cancer Targeted Technology
Phase 1 Completed
NCT04243941 2024-03-21
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05034562 2024-03-07
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04264208 2024-02-01
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Stanford University
Phase 2 Terminated
NCT03949517 2024-01-30
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford University
Phase 1/2 Completed
NCT03001869 2023-11-27
68Ga-PSMA PET/CT in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Completed
NCT03396874 2023-11-03
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
University of Michigan
Phase 2 Completed
NCT04831541 2023-09-21
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT04614363 2023-08-28
68 Ga-PSMA for High Risk Prostate Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT02659527 2023-06-15
PET/MRI in Patients With Suspected Prostate Cancer
Medical University of Vienna
Phase 3 Completed